Additions and advancements further strengthens Vium’s position to improve in vivo data insights for the world's top pharma and biotech companies
July 25, 2018
San Mateo, CA – Vium, Inc., the leading innovator for in vivo research utilizing its state-of-the-art Digital Vivarium™ and Vium Cloud approach to accelerate preclinical drug discovery and development, today announced the promotion of Laura Schaevitz, Ph.D., to Chief Scientific Officer. Additionally, the company announced the appointment of Jeff Caron to the newly formed role of Senior Vice President of Engineering and Ted Ira to Vice President of Sales.
“I am pleased to announce the promotion of Dr. Schaevitz who has been a crucial member of the Vium team for more than three years. She has played an integral role in building Vium’s in vivo drug testing platform into a world leading technology that is improving data insights and advancing drugs to clinical trials,” said Vium President and CEO Wendel Barr. “As we continue to grow and innovate as a company, we are pleased to welcome Ted and Jeff to the Vium leadership team. We believe that Jeff’s precision health technology and engineering background and Ted’s significant pharmaceutical and contract research sales and sales leadership experience will be invaluable as we continue to advance our Digital Vivarium technology to deliver breakthrough accuracy and speed in preclinical testing.”
Dr. Schaevitz has more than 20 years of experience with in vivo animal studies and has a proven track record in utilizing a broad spectrum of mouse models including transgenic models including autism, schizophrenia, Rett syndrome, and blindsight. Formerly Vice President of Scientific Technologies for Vium, she now oversees the development of Vium’s scientific program drawing upon her experiences as a molecular and behavioral neuroscientist to direct the application of Vium’s digital metrics to animal models across therapeutic areas including respiratory and inflammatory diseases.
She and her team work to enable pharmaceutical and biotechnology companies to conduct effective animal studies with predictive, continuous digital data that allows life science 1 companies to better identify and prioritize lead compounds for further investigation. Dr. Schaevitz received her Ph.D. in Neuroscience at Stanford University in 2006.
Jeff Caron joined the company as the lead digital technology executive with experience in delivering secure solution architecture and innovative healthcare and life sciences solutions. Prior to joining Vium, Caron was vice president, software engineering and chief architect at GE Healthcare where he grew the GE Life Science Digital organization to include two global engineering centers of excellence (COEs) that focused on digital solutions for drug discovery, process development, manufacturing, clinical trials decision support, and AI-driven diagnostics. Previously, Caron worked at Microsoft where he led the development of data aggregation and analytics enterprise and cloud-based platforms enabling real-time patient monitoring and population health.
Caron holds patents in methods that analyze images leveraging quantitative assays, and algorithmic techniques for diagnostics and clinical interpretation. He received his Computer Science, Mathematics degree (specialization in advanced image analysis and visualization) from Concordia University in Montreal, Canada.
Ted Ira brings more than 20 years of senior level sales and business development experience in the bioscience and health services field to Vium. Prior to joining the company, Ira was the executive director of business development for SRI International where he led the drug discovery, development, and innovative platform commercial efforts for the Biosciences division. Previously, Ira held various senior sales roles at Covance in support of its preclinical services business. Ira received a BS in Natural Resources from the University of Michigan and an MBA from the University of San Francisco.
About Vium, Inc.
Vium is the first company to create a living informatics platform for preclinical in vivo drug research. The Vium Digital Vivarium™, Vium Cloud, and online Research Suite empower scientists to optimize advances in bioengineered research models in ways previously not possible. Vium is fully accredited by AAALAC International and received an unprecedented AAALAC commendation for upholding the ‘3 Rs’, the gold-standard framework for humane animal research. Customers run the spectrum of biotechnology, pharmaceutical and computational drug discovery companies, academia, and novel therapeutic labs. Vium is backed by leading investors, including Lux Capital, Data Collective, Dolby Family Ventures, AME Cloud Ventures, Founders Fund, and Future Shape LLC. Vium is headquartered in San Mateo, California.
Media Contact: Dwain Schenck / 203-223-5230 email@example.com